BR112015022000A8 - preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação - Google Patents
preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação Download PDFInfo
- Publication number
- BR112015022000A8 BR112015022000A8 BR112015022000A BR112015022000A BR112015022000A8 BR 112015022000 A8 BR112015022000 A8 BR 112015022000A8 BR 112015022000 A BR112015022000 A BR 112015022000A BR 112015022000 A BR112015022000 A BR 112015022000A BR 112015022000 A8 BR112015022000 A8 BR 112015022000A8
- Authority
- BR
- Brazil
- Prior art keywords
- combination preparation
- pharmaceutical
- pharmaceutical composition
- present
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
PREPARAÇÃO DE COMBINAÇÃO FARMACÊUTICA, COMPOSIÇÃO FARMACÊUTICA E USO DA PREPARAÇÃO DE COMBINAÇÃO A presente invenção refere-se a uma preparação de combinação farmacêutica compreendendo fimasartan e rosuvastatina como ingredientes ativos em conjunto com meglumina. A preparação da combinação da presente invenção exibe um efeito excelente no tratamento de doenças cardiovasculares, melhorando a desintegração e a dissolução, que obtiveram melhor biodisponibilidade do fármaco e a segurança do fármaco.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130027114 | 2013-03-14 | ||
KR10-2013-0027114 | 2013-03-14 | ||
PCT/KR2014/002178 WO2014142607A1 (ko) | 2013-03-14 | 2014-03-14 | 약제학적 복합제제 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015022000A2 BR112015022000A2 (pt) | 2017-07-18 |
BR112015022000A8 true BR112015022000A8 (pt) | 2023-01-17 |
BR112015022000B1 BR112015022000B1 (pt) | 2023-06-06 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
RU2639818C2 (ru) | 2017-12-22 |
CN110123771A (zh) | 2019-08-16 |
WO2014142607A1 (ko) | 2014-09-18 |
EP2974719B1 (en) | 2019-08-28 |
BR112015022000A2 (pt) | 2017-07-18 |
CA2905686C (en) | 2017-06-27 |
MX2015011988A (es) | 2015-12-01 |
CN105120845A (zh) | 2015-12-02 |
AU2014230182A1 (en) | 2015-09-24 |
MX368148B (es) | 2019-09-20 |
US9592233B2 (en) | 2017-03-14 |
PH12015502108A1 (en) | 2016-01-18 |
MY174729A (en) | 2020-05-11 |
JP6068765B2 (ja) | 2017-01-25 |
SG11201507305SA (en) | 2015-10-29 |
JP2016512234A (ja) | 2016-04-25 |
AU2014230182B2 (en) | 2016-12-22 |
RU2015142255A (ru) | 2017-04-26 |
SA515361123B1 (ar) | 2018-04-29 |
EP2974719A1 (en) | 2016-01-20 |
ES2747098T3 (es) | 2020-03-10 |
KR101502031B1 (ko) | 2015-03-12 |
PH12015502108B1 (en) | 2016-01-18 |
EP2974719A4 (en) | 2016-08-03 |
CA2905686A1 (en) | 2014-09-18 |
US20160022679A1 (en) | 2016-01-28 |
KR20140113512A (ko) | 2014-09-24 |
ZA201507576B (en) | 2017-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
DOP2015000012A (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
IN2014DN09434A (pt) | ||
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
MY174729A (en) | Pharmaceutical combination drug | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112014017481A8 (pt) | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação | |
DOP2012000279A (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
CR20120549A (es) | Composiciones farmacèuticas que comprenden hidromorfona y naloxona | |
CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
BR112017021190A2 (pt) | composição farmacêutica e o uso da mesma | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
BR112016005601A8 (pt) | composto, composição farmacêutica, e usos de um composto | |
BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
BR112015005268A2 (pt) | seringa contendo uma composição, em particular farmacêutica, composta por imunoglobulinas, seu método de fabricação e respectivo uso | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BORYUNG CORPORATION (KR) |
|
B25G | Requested change of headquarter approved |
Owner name: BORYUNG CORPORATION (KR) |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS |